The IvyGene test is a non-invasive way of uncovering the earliest signs of malignancy. This test confirms the presence of multiple cancers, as early as stage 1.

The IvyGene Platform acts as a highly accurate biomarker to confirm multiple cancers early. Unlike many biomarkers, the IvyGene tests combine high sensitivity and specificity through a simple blood draw.

AI and Next-Generation Sequencing identified gene targets that have higher methylation levels when cancer is present. Circulating tumor DNA (ctDNA) is more highly methylated than other cell-free DNA (cfDNA) at those specific gene targets. By analyzing the methylation ratios at those specific gene targets in whole blood, the IvyGene Technology may confirm the presence of multiple cancers, as early as stage 1.